Evidence map›Paper›PMID 37540816›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.

Julie Tsu-Yu Wu, Heather A Wakelee, Summer S Han

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Lung cancer screening: where do we stand?Breathe (Sheffield, England) · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Julie Tsu-Yu WuDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-2388-1827
Heather A WakeleeDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-1136-980X
Summer S HanDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-2013-6883
Stanford University · USVA Palo Alto Health Care System · US

Funding

Evaluation of genetic, clinical, and environmental risk factors to establish effective screening strategies for second primary lung cancerR37CA226081 · NCI · STANFORD UNIVERSITY · PI HAN, SUMMER S · 2018 to 2024
$4.3M
PAtient-centered mUltidiSciplinary care for vEterans undergoing surgery (PAUSE): a hybrid 1 clinical effectiveness-implementation intervention trialI01HX003215 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI ARYA, SHIPRA · 2021 to 2025
–
HSRD VA I01 HX003215NCI NIH HHS R37 CA226081
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Early Detection of CancerLung NeoplasmsBiomarkers, TumorHumansRisk AssessmentRisk FactorsBiomarkers, Tumor

Identifiers

PMID37540816
PMCPMC10522111
OpenAlexW4385567550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.